ZIRCON Phase III Kidney Cancer Imaging Study Presented at AUA: New Data Confirms Efficacy in Masses 2cm or Smaller ...Middle East

MELBOURNE, Australia, April 30, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces additional positive results from its completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC)...

Hence then, the article about zircon phase iii kidney cancer imaging study presented at aua new data confirms efficacy in masses 2cm or smaller was published today ( Monday 01/05/2023 - 03:57 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( ZIRCON Phase III Kidney Cancer Imaging Study Presented at AUA: New Data Confirms Efficacy in Masses 2cm or Smaller )

Also on site :

• Manchester United vs Newcastle Prediction: Heavyweights Meet in Premier League’s Only Boxing Day Clash
• Sanofi to Acquire Dynavax, Adding a Marketed Adult Hepatitis B Vaccine and Phase 1/2 Shingles Candidate to the Pipeline
• Maga’s biggest fear is coming true and Trump won’t survive it